等级
pharmaceutical primary standard
API类
donepezil
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
格式
neat
InChI
1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H
InChI key
XWAIAVWHZJNZQQ-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
- Novel tacrine-donepezil hybrids for Alzheimer′s treatment: Research has led to the development of new tacrine-donepezil hybrid compounds targeting Alzheimer′s disease, offering enhanced bioactivity and potential therapeutic benefits. These hybrids demonstrate multifunctional approaches in addressing neurodegenerative disorders by combining the acetylcholinesterase inhibitory effects of donepezil with the neuroprotective properties of tacrine (Bayraktar et al., 2024).
- Role of oligodendrocytes in Alzheimer′s disease: A study explores the involvement of oligodendrocytes in Alzheimer′s pathogenesis, highlighting potential mechanisms where donepezil could be implicated in modulating neurodegenerative processes. This research underscores the broader applicability of donepezil in understanding and potentially treating Alzheimer′s disease (Wang et al., 2024).
- Shenghui decoction′s neuroprotective effects: Investigating traditional therapies, this study assesses the neuroprotective effects of Shenghui decoction in an Alzheimer′s disease model. Donepezil′s role in this context is compared, contributing to broader insights into potential integrative treatments for neurodegenerative diseases (Lu et al., 2024).
- Electrochemical sensors for Alzheimer′s drug analysis: The development of electrochemical acetylcholinesterase sensors designed for the detection and study of anti-Alzheimer drugs like donepezil underscores its importance in research and therapeutic monitoring. This advancement supports the precise administration and study of donepezil in clinical settings (Ivanov et al., 2024).
- Modulating neurodegeneration with donepezil: A study on the combined effects of endothelin receptor agonist IRL-1620 with donepezil in an amyloid-β induced model of neurodegeneration in rats, expands our understanding of donepezil′s therapeutic potential beyond traditional applications, suggesting its utility in complex therapeutic regimes (Mahajan et al., 2024).
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
Acute Tox. 2 Oral - Eye Irrit. 2
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Marwan Sabbagh et al.
BMC geriatrics, 13, 56-56 (2013-06-08)
Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated
Manabu Ikeda et al.
Dementia and geriatric cognitive disorders, 36(3-4), 229-241 (2013-08-21)
To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized
Yusuke Yatabe et al.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 13(2), 88-93 (2013-08-06)
With the recent approval of several new drugs, pharmacological management of Alzheimer's disease has become more complicated in Japan. The efficacy and safety of increasing the dose of donepezil to 10 mg daily were assessed in an open-label study of patients
Warren B Zigman
Developmental disabilities research reviews, 18(1), 51-67 (2013-08-21)
At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979
H Sugimoto et al.
Current medicinal chemistry, 7(3), 303-339 (2000-01-19)
A wide range of evidence shows that acetylcholinesterase (AChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The successful development of these compounds was based on a well-accepted theory that the decline in cognitive and mental functions associated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门